Last Updated: November 16, 2026

Details for Patent: 9,157,082

« Back to Dashboard


Summary for Patent: 9,157,082
Title:Modulation of apolipoprotein CIII (ApoCIII) expression
Abstract:Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing HDL levels and/or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disorder, or a symptom thereof.
Inventor(s):Adam Mullick, Rosanne M. Crooke, Mark J. Graham, Kenneth W. Dobie, Richard Lee
Assignee: Ionis Pharmaceuticals Inc
Application Number:US14/114,187
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,157,082
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 9,157,082

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ionis Pharms Inc TRYNGOLZA (AUTOINJECTOR) olezarsen sodium SOLUTION;SUBCUTANEOUS 218614-002 Jun 24, 2026 RX Yes Yes 9,157,082 ⤷  Start Trial USE IN REDUCING TRIGLYCERIDES AND THE RISK OF ACUTE PANCREATITIS IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG: TG GREATER THAN OR EQUAL TO 500 MG/DL) ⤷  Start Trial
Ionis Pharms Inc TRYNGOLZA (AUTOINJECTOR) olezarsen sodium SOLUTION;SUBCUTANEOUS 218614-001 Dec 19, 2024 RX Yes Yes 9,157,082 ⤷  Start Trial USE IN REDUCING TRIGLYCERIDES IN ADULTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) ⤷  Start Trial
Ionis Pharms Inc TRYNGOLZA (AUTOINJECTOR) olezarsen sodium SOLUTION;SUBCUTANEOUS 218614-001 Dec 19, 2024 RX Yes Yes 9,157,082 ⤷  Start Trial USE IN REDUCING TRIGLYCERIDES AND THE RISK OF ACUTE PANCREATITIS IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG: TG GREATER THAN OR EQUAL TO 500 MG/DL) ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,157,082

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2012249324 ⤷  Start Trial
Australia 2017200025 ⤷  Start Trial
Australia 2019201011 ⤷  Start Trial
Brazil 112013027479 ⤷  Start Trial
Canada 2834232 ⤷  Start Trial
China 103547271 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.